EPO and kidney disorder: HDP-low represented 45% of the HDP cohort and were characterized by alterations in genes associated with pre-existing chronic inflammation, cell cycle, EPO-related pathways, reduced expression of B cell-related genes at baseline, and genes potentially correlated with renal disease, while further differences emerged in genes involved in B cell regulation and survival at day 7.